Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ventyx Biosciences (VTYX)
NASDAQ:VTYX
Holding VTYX?
Track your performance easily
VTYX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.79 - $15.81
Previous Close$2.18
Volume571.15K
Average Volume (3M)1.21M
Market Cap
$154.06M
Enterprise Value-$74.11M
Total Cash (Recent Filing)$239.44M
Total Debt (Recent Filing)$11.27M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Mar 20, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.79
Shares Outstanding70,669,131
10 Day Avg. Volume814,068
30 Day Avg. Volume1,213,609
Standard Deviation0.49
R-Squared0.00133
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)0.55
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.43
Forecast
1Y Price Target
$11.29Price Target Upside417.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Ventyx Biosciences News
PremiumStock Analysis & Ideas
These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say Analysts
PremiumCompany Announcements
Ventyx Biosciences Announces Executive Financial Officer Changes
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentVentyx plans to initiate a 28-day Phase 2a study with VTX3232 in early Parkinson’s disease, as well as a separate 12-week Phase 2a study in patients with obesity and additional cardiovascular and cardiometabolic risk factors.
Financial StabilityVentyx exited the second quarter with $279.7M cash and cash equivalents, which management estimates will be sufficient to fund operations into 2H26.
Strategic InvestmentVentyx announced a $27M strategic investment from Sanofi at a converted price of $3.82/share (+66% premium to yesterday's close) in exchange for an exclusive right of first negotiation for certain program rights related to Ventyx's CNS-penetrant NLRP3 inhibitor, VTX3232.
Bears Say
Clinical TrialsThe company announced the disappointing Phase IIb HARMONY trial results for VTX958 (TYK2 inhibitor) in Crohn’s disease, followed by the decision to pause the pursuit of the CD program.
Competitive LandscapeCompetition in the oral obesity space is heating up with recent early win from Roche's oral GLP-1 agonist.
PartnershipsThe $27M is less than one quarter in operating expenses for the company and does not commit Sanofi to partnering on the program or licensing VTX3232 from the company.
---
Ownership Overview
28.38% Insiders
15.76% Mutual Funds
0.10% Other Institutional Investors
46.56% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VTYX FAQ
What was Ventyx Biosciences’s price range in the past 12 months?
Ventyx Biosciences lowest stock price was $1.79 and its highest was $15.80 in the past 12 months.
What is Ventyx Biosciences’s market cap?
Currently, no data Available
When is Ventyx Biosciences’s upcoming earnings report date?
Ventyx Biosciences’s upcoming earnings report date is Mar 20, 2025 which is in 136 days.
How were Ventyx Biosciences’s earnings last quarter?
Ventyx Biosciences released its earnings results on Aug 08, 2024. The company reported -$0.45 earnings per share for the quarter, beating the consensus estimate of -$0.579 by $0.129.
Is Ventyx Biosciences overvalued?
According to Wall Street analysts Ventyx Biosciences’s price is currently Undervalued.
Does Ventyx Biosciences pay dividends?
Ventyx Biosciences does not currently pay dividends.
What is Ventyx Biosciences’s EPS estimate?
Ventyx Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ventyx Biosciences have?
Ventyx Biosciences has 70,669,130 shares outstanding.
What happened to Ventyx Biosciences’s price movement after its last earnings report?
Ventyx Biosciences reported an EPS of -$0.45 in its last earnings report, beating expectations of -$0.579. Following the earnings report the stock price went up 4.545%.
Which hedge fund is a major shareholder of Ventyx Biosciences?
Among the largest hedge funds holding Ventyx Biosciences’s share is Deerfield Management Company, LP. It holds Ventyx Biosciences’s shares valued at 13M.
---
Ventyx Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.29 (417.89% Upside)
$11.29 (417.89% Upside)
Blogger Sentiment
Neutral
VTYX Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 3.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.2%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.19%
12-Months-Change
Fundamentals
Return on Equity
-56.29%
Trailing 12-Months
Asset Growth
-11.35%
Trailing 12-Months
Company Description
Ventyx Biosciences
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
---
VTYX Earnings Call
Q1 2024
0:00 / 0:00
---
VTYX Stock 12 Month Forecast
Average Price Target
$11.29
▲(417.89% Upside)
Technical Analysis
Best Analysts Covering VTYX
1 Year
1 Year Success Rate
7/22 ratings generated profit
1 Year Average Return
-13.93%
assigned a buy rating 3 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 31.82% of your transactions generating a profit, with an average return of -13.93% per trade.
---